

Hikma remains constituent of the FTSE4Good Index Series for 5th consecutive year

London, 29 July 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's, stable / BB+ S&P, positive) the multinational generic pharmaceutical company announced today that it remains a constituent of the FTSE4Good Index Series. The FTSE4Good Index Series was created by the global index and data provider FTSE Russell and is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by investors to create and assess responsible investment funds and other products.

"We are pleased that Hikma has remained in the FTSE4Good Index Series for the fifth straight year," said Hana Ramadan, head of CSR. "This is a strong acknowledgement of our long-standing commitment to quality, governance and integrity."

"We have prioritised our activities around five Sustainable Development Goals (SDGs) that most closely align with our business and social engagement strategy: Good Health and Wellbeing, Quality Education, Gender Equality, Decent Work and Economic Growth, Industry, as well as Innovation and Infrastructure," she added.

For more than a decade, Hikma has been an active member of the UN Global Compact (UNGC), the world's largest corporate sustainability initiative mobilising companies to do business responsibly by aligning their strategies and operations with principles on human rights, labour, environment and anti-corruption; and to take strategic actions to advance broader societal goals, such as the UN Sustainable Development Goals, with an emphasis on collaboration and innovation.

-- ENDS --



Enquiries

Hikma Pharmaceuticals PLC

Brooke Clarke
Vice President Corporate Affairs

+44 (0)20 7399 2795
brooke@hikma.uk.com

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.